Mobilise-D
Mobilise-D is a European research consortium (2019-2024) that validated 25 Digital Mobility Outcomes algorithms using body-worn sensors across 2,382 patients in four disease cohorts, serving pharmaceutical R&D, clinicians, and regulators via open-source tools and the Empatica platform.
- Company typePrivate
- Founded2019
- Headquarters—
- Headcount—
- GTM typeB2B
- OfferingSoftware
What Mobilise-D does
Mobilise-D is a European research consortium, not a commercial company, that was formed in 2019 to produce validated Digital Mobility Outcomes (DMOs) for monitoring real-world walking using body-worn inertial sensors. Between 2019 and June 2024 it operated under a €50 million grant from the IMI2 Joint Undertaking (EU Horizon 2020 plus EFPIA), coordinated by Newcastle University and Novartis, and assembled more than 300 researchers from 34 universities, hospitals, and industry partners. Its core deliverable is a set of 25 validated algorithms — including real-world walking speed as the primary outcome — extracted from accelerometer and gyroscope data and clinically validated across four patient cohorts (COPD, Parkinson's disease, multiple sclerosis, proximal femoral fracture) covering 2,382 patients at 17 EU clinical sites.
The technology stack combines a validated device-algorithm pair, the open-source MobGap Python pipeline (released on GitHub and Zenodo), and standardized technical and clinical validation protocols that achieved EMA Letters of Support in 2020 and 2021 and ongoing engagement with the FDA via pre-Letter of Intent. Outputs are openly published, including the underlying datasets from the Technical Validation Study (2020-2022) and Clinical Validation Study (2021-2024). In July 2024 Mobilise-D licensed its validated DMOs into Empatica's commercial Health Monitoring Platform, the first commercial deployment of the algorithms.
The consortium has no commercial revenue model: funding came from the IMI2 grant, outputs are publicly distributed, and there is no published pricing. Its go-to-market is community-led — patient and public advisory groups, scientific publications, open-source repositories, webinars, summer schools, and an annual conference. With the IMI project concluded in June 2024, follow-on activities are housed in two successor structures: SUSTAIN Mobilise-D (an industry-funded consortium led by Dan Rooks and Brian Caulfield that manages algorithm and data sharing) and the Mobilise-D Network (an open membership research community launched June 2024). Primary stakeholders are pharmaceutical R&D organizations, clinicians treating mobility-affecting conditions, regulatory bodies (EMA, FDA), and the patient cohorts themselves.
Mobilise-D firmographics
Firmographics- Name
- Mobilise-D
- Legal name
- Mobilise-D
- Website
- https://mobilise-d.eu
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Short description
- Mobilise-D is a European research consortium (2019-2024) that validated 25 Digital Mobility Outcomes algorithms using body-worn sensors across 2,382 patients in four disease cohorts, serving pharmaceutical R&D, clinicians, and regulators via open-source tools and the Empatica platform.
- Ownership category
- akta.pro rank
Mobilise-D industry classification
Industry- Product category
- Digital Health Technology
- NAICS
- Geophysical Surveying and Mapping Services (541360)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking) (HLAHACAI)
- akta.pro secondary industries
- Post-Acute Care & Rehabilitation Monitoring (Home Health, PT/OT) (HLACAPAE), Post-Acute, Rehabilitation & Home Recovery Monitoring (PT/OT, post-surgical) (HLALAFAE)
Keywords
Mobilise-D business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- IMI Research Funding: Funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative. Mobilise-D received funding from IMI 2 Joint Undertaking under grant agreement No. 820820, with support from the European Union's Horizon 2020 research programme and EFPIA (European Federation of Pharmaceutical Industries and Associations)
Go-to-market motion1 record
Distribution channels4 records
Marketing channels9 records
Mobilise-D product offering
Product offeringCore offering
Mobilise-D developed and validated a set of 25 Digital Mobility Outcomes (DMOs) and associated algorithms that measure real-world walking and mobility using body-worn inertial sensors, targeting clinical trials and therapeutic development for mobility-affecting conditions. The validated algorithms, open-source analysis pipeline (MobGap), and clinical datasets are distributed through GitHub and Zenodo, with commercial integration through Empatica's Health Monitoring Platform. Outputs were pursued for regulatory endorsement via the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
Product overview
Mobilise-D is a research consortium and technology platform that provides validated Digital Mobility Outcomes (DMOs) for measuring real-world walking and mobility using body-worn sensors. The core product consists of 25 validated mobility outcomes and associated algorithms developed through a 5-year IMI-funded project (2019-2024). The technology portfolio includes the validated device-algorithm pair, the MobGap open-source tool, and data sharing platforms via GitHub and Zenodo. The ecosystem consists of the original Mobilise-D IMI research project, the follow-on SUSTAIN Mobilise-D consortium, and the Mobilise-D Network for ongoing collaboration and dissemination of digital mobility assessment methods.
Differentiator
Problem solved
Functional benefit
Products and services
- Digital Mobility Outcomes (DMOs) Validated set of algorithms and methods to measure digital mobility outcomes including real-world walking speed (RWS) as primary outcome and other mobility parameters as secondary outcomes, designed for clinical validation and regulatory endorsement. Available to pharmaceutical companies, clinical trial sponsors, and researchers developing treatments for mobility-affecting conditions.
- MobGap Open-source tool for mobility assessment with wearable devices, enabling external researchers and industry to implement real-world mobility assessment in clinical trials and research studies.
- Mobilise-D Data Sharing Platform Open data repository providing access to comprehensive datasets from the Technical Validation Study (TVS, 2020-2022) and Clinical Validation Study (CVS, 2021-2024), including algorithms and code shared via GitHub and Zenodo for researchers.
Quantifiable outcome
- Recruitment of 2,382 patients exceeding targets across four disease cohorts
- +3 more outcomes
Companies that use Mobilise-D
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Mobilise-D technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability3 records
Feature4 records
Mobilise-D partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and supporting.
- EmpaticacoreStrategic partnership to integrate validated Digital Mobility Outcomes (DMOs) into Empatica's Health Monitoring Platform. This partnership provides users of Empatica's wearables access to 25 validated mobility outcomes, addressing the demand for high-quality digital measures in clinical trials and therapeutic development.
- Critical Path Institute (C-Path)coreCollaboration agreement to advance the use of digital health technologies in clinical trials. Focus areas include sharing learning from regulatory interactions, verification and validation of digital tools, patient-centered outcome measurements, and development of open-source platforms. C-Path is an independent nonprofit public-private partnership with the FDA.
- Cure Parkinson's UKcoreStrategic partnership to accelerate translation of research into clinical practice. Aims to bring research and clinical studies closer to patients and the public, with focus on improving mobility assessment in Parkinson's disease trials and patient care.
- NEURONETsupportingCollaboration agreement as part of Mobilise-D's strategic collaboration policy to extend outreach and transition to sustainability through enhanced communication and long-lasting relationships.
- Voice GlobalsupportingPartnership using the Voice Global platform for Patient and Public Involvement and Engagement (PPIE) activities. Enables organization of research opportunities, communication, and discussion forums including the Patient and Public Advisory Group (PPAG) and Patient Forum.
- IDEA-FASTsupportingCollaboration between two EU IMI projects to strengthen research and development of digital biomarkers. Joint efforts in ethics, data-sharing, regulatory approaches, dissemination activities, creation of a Digital Health Academy, and working with target populations.
Scale indicators7 records
Recent moves8 records
Expansion highlights5 records
Mobilise-D competitors and assessment
Company assessmentDirect peers
- Koneksa Health: Koneksa Health develops validated digital biomarkers from wearable sensors for use as clinical trial endpoints across multiple therapeutic areas. It is a direct peer to Mobilise-D because both focus on generating regulatory-grade evidence for wearable-derived endpoints in chronic disease populations.
- Biofourmis: Biofourmis builds a remote patient monitoring and digital biomarker platform used in clinical trials and care delivery for chronic conditions. It is a direct peer to Mobilise-D in producing wearable-derived digital biomarkers and RPM analytics for pharmaceutical sponsors.
- APDM Wearable Technologies (a Clario company): APDM develops validated wearable sensors and mobility outcomes (e.g., Opal sensors, Mobility Lab) widely used in Parkinson's, MS, and frailty research. It is a direct peer to Mobilise-D in wearable mobility assessment across the same neurological and chronic disease populations.
- IXICO: IXICO provides digital analytics and biomarker services for neurodegenerative disease trials, with growing work in digital mobility outcomes for Parkinson's and similar indications. It is a direct peer to Mobilise-D in academic-grade digital biomarker analytics serving pharma clinical development.
- ActiGraph: ActiGraph designs and manufactures wearable actigraphy and inertial sensor hardware, plus the CentrePoint software platform used in clinical trials and academic research. It is a direct peer to Mobilise-D in providing validated body-worn sensors and analytics for real-world mobility and activity assessment.
- VivoSense: VivoSense develops and qualifies digital endpoints and wearable sensor algorithms for clinical trials, with deep regulatory engagement with FDA and EMA. It is a direct peer to Mobilise-D in turning real-world wearable sensor data into accepted regulatory endpoints across chronic disease indications.
- Evidation Health: Evidation Health measures real-world health outcomes using consumer wearables and connected sensors, and partners with pharma on digital endpoint development. It is a direct peer to Mobilise-D in generating evidence-based digital measures from continuous wearable data for clinical research.
Broad incumbents
- Medidata (Dassault Systèmes): Medidata provides the industry's leading clinical trial data platform and is expanding into sensor and wearable-derived endpoint capture. It is a broad incumbent peer to Mobilise-D as a sponsor-facing platform that can ingest and operationalize competing mobility endpoints.
- ICON plc: ICON is a global CRO with embedded digital health, wearables, and decentralized trial capabilities (including former PRA Health and Symphony Clinical Research). It is a broad incumbent peer to Mobilise-D because it can operationalize — or compete with — validated digital mobility endpoints across multi-trial programs.
- Clario: Clario is a large clinical trial technology vendor offering endpoint collection including wearables, eCOA, and imaging. It is a broad incumbent peer to Mobilise-D because it integrates competing wearable-derived mobility endpoints (via its APDM acquisition) into commercial trial delivery.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
Mobilise-D social profiles
Digital presenceMobilise-D financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mobilise-D leadership team
Management profileNumber of profiles
Profiles14 records
Mobilise-D subsidiaries and ownership
Company hierarchySubsidiaries2 records
Mobilise-D funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mobilise-D M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mobilise-D
What does Mobilise-D do?
Mobilise-D developed and validated a set of 25 Digital Mobility Outcomes (DMOs) and associated algorithms that measure real-world walking and mobility using body-worn inertial sensors, targeting clinical trials and therapeutic development for mobility-affecting conditions. The validated algorithms, open-source analysis pipeline (MobGap), and clinical datasets are distributed through GitHub and Zenodo, with commercial integration through Empatica's Health Monitoring Platform. Outputs were pursued for regulatory endorsement via the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
Is Mobilise-D a public or private company?
Mobilise-D is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Mobilise-D founded?
Mobilise-D was founded in 2019.
How does Mobilise-D make money?
One revenue line is on record: IMI Research Funding.
Who are Mobilise-D's main competitors?
Direct peers on record are Koneksa Health, Biofourmis, APDM Wearable Technologies (a Clario company), IXICO, ActiGraph, VivoSense and Evidation Health. Broad incumbents are Medidata (Dassault Systèmes), ICON plc and Clario.
Does Mobilise-D have an API?
No public API is recorded for Mobilise-D.
What industry is Mobilise-D in?
Mobilise-D's product category is Digital Health Technology. Its primary akta.pro industry code is HLAHACAI, Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking), with a secondary code of HLACAPAE, Post-Acute Care & Rehabilitation Monitoring (Home Health, PT/OT). Its NAICS code is 541360 and its SIC code is 8731.